No abstract available.
Hodgkin Disease* ; Radiotherapy*

Background: Treatment of Hodgkin\u2019s disease with ABVD followed by low-dose involved field of radiotherapy is currently considered the standard of care. Objectives: This study was evaluated the efficacy and some pronogstic factors. Subjects and method: 103 consecutive patients with newly diagnosed HD\ufffd?disease treated with combination CT and RT at K-hospital between 10/2001 \ufffd?3/2005 were eligible. The end points of the study were complete response (CR), relapse-free survival (RFS), overall survival (OS). Tests were used for analysis: chi-square test, Kaplan-Meier method... Results: 103 patients (100%) achieved a CR. The RFS and OS rate at 5 years were 64,6% and 91,7%. Pronogstic factors are sex, anemia, B symtom, liver lesion. Conclusion: Treatment plan has brought the most effective so far. Liver damage is a bad influence markedly the survival time.
Hodgkin Disease/ radiotherapy ;

No abstract available.
Hodgkin Disease* ; Lymphoma, Non-Hodgkin* ; Radiotherapy*

Primary hypothyroidism commonly occurs after radiotherapy (RT), and coincides with increased circulating thyroid-stimulating hormone (TSH) levels.We tested therefore the protective effect of suppressing TSH with L-thyroxine during RT for medulloblastoma/PNET and Hodgkin lymphoma (HL) in a prospective cohort study. From1998 to 2001, a total of 37 euthyroid children with medulloblastoma/PNET plus 14 with HL, scheduled for craniospinal irradiation and mediastinum/neck radiotherapy, respectively, underwent thyroid ultrasound and free triiodothyronine (FT3), free thyroxine (FT4), and TSH evaluation at the beginning and end of craniospinal iiradiation. From 14 days before and up to the end of radiotherapy, patients were administered L-thyroxine checking every 3 days TSH to ensure a value < 0.3 μIU/mL. During follow-up, blood tests and ultrasound were repeated; primary hypothyroidism was considered an increased TSH level greater than normal range. Twenty-two/37 patients with medulloblastoma/PNET and all the 14 patients with HL were alive after a median 231 months from radiotherapy with 7/22 and 8/14 having correctly reached TSH levels < 0.3 μIU/mL and well matched for other variables. Twenty years on, hypothyroidism-free survival rates differed significantly, being 60% ± 15% and 15.6% ± 8.2% in TSH-suppressed vs. not-TSH suppressed patients, respectively (P = 0.001). These findings suggest that hypothyroidism could be durably prevented in two populations at risk of late RT sequelae, but it should be confirmed in a larger cohort.
Cerebellar Neoplasms ; Child ; Hodgkin Disease/radiotherapy* ; Humans ; Hypothyroidism/prevention & control* ; Medulloblastoma/radiotherapy* ; Prospective Studies ; Thyrotropin

Female ; Hodgkin Disease ; radiotherapy ; Humans ; Middle Aged ; Nose Neoplasms ; radiotherapy ; Radiotherapy ; adverse effects ; Vocal Cord Paralysis ; etiology

Classical Hodgkin lymphoma (cHL) is a highly curable disease, but the prognosis for relapsed/refractory cHL is grave. Pembrolizumab has recently shown impressive effects in patients with relapsed/refractory cHL in a phase Ib study (KEYNOTE-013). This report presents a case of a 17-year-old male with refractory cHL who received multiple chemotherapy regimens and radiotherapies, including brentuximab vedotin. Following both the second and fourth cycles of intravenous pembrolizumab 100 mg (2 mg/kg), positron emission tomography/computed tomography (PET/CT) scan showed progression. However, because performance status and fever improved, treatment was continued, and complete remission was confirmed by PET/CT after eight cycles of pembrolizumab. This case suggests that clinicians need to be aware of the potential for pseudoprogression in patients treated with pembrolizumab.
Adolescent ; Drug Therapy ; Electrons ; Fever ; Hodgkin Disease* ; Humans ; Male ; Positron-Emission Tomography and Computed Tomography ; Prognosis ; Radiotherapy

Radiotherapy result of 162 patients with stage I, II Intermediate Grade Non-Hodgkin's lymphoma was analyzed to clarify the role and limit of radiotherapy. Of 68 initial failures, 38.2% stageI was 30.0% and 70.0%, respectively with involved field treatment and was 43.8% and 56.2% with extended field treatment, respectively; in stageII, was 16.7% and 83.3%, 41.7% and 58.3% and 40.4% for patients with stage I and II, respectively. The survival was significantly different by stage. Bulky tumors (> or =10 cm) and B symptoms didn't influence prognosis significantly. The 5 year disease free survival with extended or wide field was better than that with involved field especially in stage I. Overall survival rates for all patients, patients with stageI, and II disease were 57.7%, 65.3% and 52.2%, respectively, after survival gain of the salvage chemotherapy was combined. But the overall survival of stageI disease was not better than that of stageII disease. Thus, extended field was required to achieve better disease free survival and relapsed cases might gain with chemotherapy.
Disease-Free Survival ; Drug Therapy ; Humans ; Lymphoma, Non-Hodgkin* ; Prognosis ; Radiotherapy* ; Survival Rate

The 16 cases of patient with Hodgkin's disease admitted to Department of Pediatrics. Yonsei Cancer Center, Collage of Medicine, Yonsei University during 15 years from January 1975 to December 1989 were reviewed on the basis of clinical charicteristics, treatment and survival rate. The results were summerized as follows. 1) The mean age of patients was 7.6 4.1(range 2~15 years of age). 2) The clinical symptoms and signs were fever (50%), cervical lymphoadenpathy (44%), weight loss(25%), night sweat sweat(19%), hepatomegaly (13%) in order. 3) The stage by Ann Arbor classification revealed Stage I (19%), Stage II (37%), Stage III (19%), stage IV (25%). 4) The histologic subtype of the 14 cases confirmed by Rye Classification revealed that mixed cellularity type (57%) was the most common and lymphocyte predominant type (28%), nodular 5) The seven patients were treated by combind modality therapy, and the six patients by chemotherapy only and the three patients by radiotherapy only. 6) Overall 5 year survival rate was 69% in all patients, and 100% in Stage I, II, 67% in Stage III, but the patients of Stage IV were all died within 7 months.
Classification ; Drug Therapy ; Fever ; Hepatomegaly ; Hodgkin Disease* ; Humans ; Lymphocytes ; Pediatrics ; Radiotherapy ; Secale ; Survival Rate ; Sweat

Thirty eight patients with stage Iand II primary gastrointestinal non-Hodgkin's lymphoma were treated in the Department of Therapeutic Radiology, Seoul National University Hospital between 1979 and 1984. There were 6 systemic disseminations during radiotherapy, and the overall failure rate were 31% in the cases with tumor bulk less than 5 cm in diameter before radiotherapy and 75% in the cases with tumor bulk greater than 5 cm in diameter (p<0.05). The overall 5 year survival rate were 69.2% in 28 patients who completed radiotherapay and 72% in 24 patients with tumor bulk less than 5 cm in diameter (small or no tumor bulk). The 5 year disease free survival rate were 71% in cases with tumor bulk less than 5 cm in diameter and 25% in cases with tumor bulk greater than 5 cm in diameter (p<0.01). But the initial stage was not related with treatment result in all cases or subgroups of cases. Thus the cases with small or no tumor bulk were shown to be curable with combined surgery and postoperative radiotherapy, but for the control of the cases with large tumor bulk that had a guarded prognosis combined radiotherapy and chemotherapy should be tried.
Disease-Free Survival ; Drug Therapy ; Humans ; Lymphoma, Non-Hodgkin* ; Prognosis ; Radiation Oncology ; Radiotherapy* ; Seoul ; Survival Rate

Most lymphoma occurs within the lymph node. A small portion of the lymphoma can have extranodal involvements such as the oral cavity, oropharynx, nasopharynx, paranasal sinuses, and larynx, etc. Especially, Hodgkin's lymphoma with primary manifestation in the palatine tonsil is an extremely rare entity and seldom documented in the literature. Recently, we experienced a case of palatine tonsil mass as a first symptom of Hodgkin's lymphoma. The patient underwent a surgical excision and radiotherapy. The authors report the first case of Hodgkin's lymphoma of the palatine tonsil in Korea with a review of literature.
Hodgkin Disease* ; Humans ; Korea ; Larynx ; Lymph Nodes ; Lymphoma ; Mouth ; Nasopharynx ; Oropharynx ; Palatine Tonsil* ; Paranasal Sinuses ; Radiotherapy